Abstract:Background: The main challenge against patients with cancer to derive benefits from immune checkpoint inhibitors targeting PD-1/PD-L1 appears to be the immunosuppressive tumor microenvironment (TME), in which IL-33/ST2 signal fulfills critical functions. However, whether IL-33 limits the therapeutic efficacy of anti-PD-L1 remains uncertain. Methods: Molecular mechanisms of IL-33/ST2 signal on anti-PD-L1 treatment lewis lung carcinoma tumor model were assessed by RNA-seq, ELISA, WB and immunofluorescence (IF). A sST2-Fc fusion protein was constructed for targeting IL-33 and combined with anti-PD-L1 antibody for immunotherapy in colon and lung tumor models. On this basis, bifunctional fusion proteins were generated for PD-L1-targeted blocking of IL-33 in tumors. The underlying mechanisms of dual targeting of IL-33 and PD-L1 revealed by RNA-seq, scRNA-seq, FACS, IF and WB. Results: After anti-PD-L1 administration, tumor-infiltrating ST2+ regulatory T cells (Tregs) were elevated. Blocking IL-33/ST2 signal with sST2-Fc fusion protein potentiated antitumor efficacy of PD-L1 antibody by enhancing T cell responses in tumor models. Bifunctional fusion protein anti-PD-L1-sST2 exhibited enhanced antitumor efficacy compared with combination therapy, not only inhibited tumor progression and extended the survival, but also provided long-term protective antitumor immunity. Mechanistically, the superior antitumor activity of targeting IL-33 and PD-L1 originated from reducing immunosuppressive factors, such as Tregs and exhausted CD8+ T cells while increasing tumor-infiltrating cytotoxic T lymphocyte cells. Conclusions: In this study, we demonstrated that IL-33/ST2 was involved in the immunosuppression mechanism of PD-L1 antibody therapy, and blockade by sST2-Fc or anti-PD-L1-sST2 could remodel the inflammatory TME and induce potent antitumor effect, highlighting the potential therapeutic strategies for the tumor treatment by simultaneously targeting IL-33 and PD-L1.

Macrophages reprogramming improves immunotherapy of IL-33 in peritoneal metastasis of gastric cancer

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

CAF-macrophage Crosstalk in Tumour Microenvironments Governs the Response to Immune Checkpoint Blockade in Gastric Cancer Peritoneal Metastases

Mouse Forestomach Carcinoma Cells Immunosuppress Macrophages Through Transforming Growth Factor-Β1

Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment Through CD8+ T and NK Cells

The IL-33/ST2 Axis Affects Tumor Growth by Regulating Mitophagy in Macrophages and Reprogramming Their Polarization.

Mir-182 Targeting Reprograms Tumor-Associated Macrophages and Limits Breast Cancer Progression

Exogenous IL-33 promotes tumor immunity via macroscopic regulation of ILC2s

Interleukin‐33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage‐Mediated Shedding Mechanism

Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy

A polymeric nanoplatform enhances the cGAS-STING pathway in macrophages to potentiate phagocytosis for cancer immunotherapy

Intraperitoneal programming of tailored CAR macrophages via mRNA-LNP to boost cancer immunotherapy

The PDGF-BB-SOX7 Axis-Modulated IL-33 in Pericytes and Stromal Cells Promotes Metastasis Through Tumour-Associated Macrophages

Tumoral expression of IL-33 promotes Anti-tumor Immune Responses (TUM2P.912)

IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization

Oesophageal squamous cell carcinoma-associated IL-33 rewires macrophage polarization towards M2 via activating ornithine decarboxylase

Poor Clinical Outcomes and Immunoevasive Contexture in Intratumoral IL-10-Producing Macrophages Enriched Gastric Cancer Patients

In Situ Reprogramming of Tumor-Associated Macrophages Enhances Cancer Immunotherapy

Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer

MiR-548t-5p regulates pancreatic ductal adenocarcinoma metastasis through an IL-33-dependent crosstalk between cancer cells and M2 macrophages

Molecular Mechanisms of IL-33-mediated Stromal Interactions in Cancer Metastasis.